Panel Discussion: Exploring Opportunities in Alpha-Synuclein & Beyond for More Transformative & Efficacious Therapies: What’s Coming Next in Parkinson’s Drug Development?
Time: 4:30 pm
day: Conference Day One PM
Details:
- Taking learnings from targeting amyloid plaques, what is the rationale for targeting synuclein fibrils?
- What are the promising PD targets beyond alpha-synuclein? What can we expect to see in the next few years?
- What are the latest advancements in diagnostic tools like alpha-synuclein PET tracers and what potential do these hold?
- What are the earlier efforts in development to discover new PD targets?
